<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hypoxic preconditioning (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>) initiates intracellular signaling pathway to provide protection against subsequent cerebral ischemic injuries, and its mechanism may provide molecular targets for therapy in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>According to our study of conventional protein kinase C βII (cPKCβII) activation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>, the role of cPKCβII in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>-induced neuroprotection and its interacting proteins were determined in this study </plain></SENT>
<SENT sid="2" pm="."><plain>The autohypoxia-induced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> and middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO)-induced <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> mouse models were prepared as reported </plain></SENT>
<SENT sid="3" pm="."><plain>We found that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> reduced 6 h MCAO-induced neurological deficits, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:hpo ids='HP_0000969'>edema</z:hpo> ratio and cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in peri-<z:mpath ids='MPATH_124'>infarct</z:mpath> region (penumbra), but cPKCβII inhibitors Go6983 and LY333531 blocked <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>-induced neuroprotection </plain></SENT>
<SENT sid="4" pm="."><plain>Proteomic analysis revealed that the expression of four proteins in cytosol and eight proteins in particulate fraction changed significantly among 49 identified cPKCβII-interacting proteins in cortex of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> mice </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> could inhibit the decrease of phosphorylated collapsin response mediator protein-2 (CRMP-2) level and increase of CRMP-2 breakdown product </plain></SENT>
<SENT sid="6" pm="."><plain>TAT-CRMP-2 peptide, which prevents the cleavage of endogenous CRMP-2, could inhibit CRMP-2 dephosphorylation and proteolysis as well as the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume of 6 h MCAO mice </plain></SENT>
<SENT sid="7" pm="."><plain>This study is the first to report multiple cPKCβII-interacting proteins in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> mouse brain and the role of cPKCβII-CRMP-2 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>-induced neuroprotection against early stages of ischemic injuries in mice </plain></SENT>
</text></document>